Evidence map›Paper›PMID 25787339›Full record

ArticleDrug delivery and translational research2015

Development and optimization of novel controlled-release pioglitazone provesicular powders using 3² factorial design.

Marwa H Shukr, Nadia A Eltablawy

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Marwa H ShukrDepartment of Pharmaceutics, National Organization for Drug Control and Research, Giza, Egypt, marwa_25_2001@hotmail.com.
Nadia A Eltablawy

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This work aimed at studying a novel controlled drug delivery proniosomal formulation of pioglitazone for treatment of diabetes type-2. The effects of independent variables like type of surfactant and ratio of surfactants/cholesterol were studied using 3(2) factorial design. The provesicular powders were characterized regarding their encapsulation efficiency, vesicle size, morphology, and in vitro drug release. The revealed optimal provesicular powder was exposed to stability testing and in vivo performance evaluation. Results showed that F6 was selected as the optimal formulation, and its in vivo hypoglycemic effect on normal healthy and STZ-induced diabetic albino rats was investigated. F6 proniosomal formulation exhibited a significantly higher % decrease (56.18 % for STZ-induced diabetic albino rats) of blood glucose level (BGL) than Actos® (32. % for STZ-induced diabetic albino rats). Higher % decrease of BGL with longer t max and lower AUC0-24 confirms the development of a successful proniosomal pioglitazone formulation.

Indexed as

AnimalsBlood GlucoseChemistry, PharmaceuticalCholesterolDelayed-Action PreparationsDiabetes Mellitus, ExperimentalDrug LiberationDrug StabilityHypoglycemic AgentsLiposomesPioglitazonePowdersRatsSurface-Active AgentsThiazolidinedionesBlood GlucoseCholesterolDelayed-Action PreparationsHypoglycemic AgentsLiposomesPioglitazonePowdersSurface-Active AgentsThiazolidinediones

Identifiers

PMID25787339

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.